EGFR A763_Y764insFQEA

CI-VAR-00000132Explore in graph →NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAlaNM_001346898.1:c.2290_2291insTCCAGGAAGCCTCIViC 1515 rs397517106

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR A763_Y764insFQEA	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4647 In a lung adenocarcinoma patient harboring EGFR A763_Y764insFQEA mutation, EGFR A763_Y764insFQEA was associated with partial response to treatment with erlotinib in combination with chemotherapy. PMID 23371856 · Arcila et al., 2013 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma7
EGFR A763_Y764insFQEA	Erlotinib	Predictive	B	Supports Sensitivity Response	2	submitted	EID5939 Out of a group of 19 EGFR exon 20 insertion NSCLC patients, 3 patients had EGFR M766_A767insASV mutation. One patient was 69 year old female neversmoker lung adenocarcinoma patient was given erlotini… (full text at CIViC) PMID 24353160 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.